Olanzapine or prochlorperazine added to antiemetic therapy for persistent chemotherapy-induced nausea: an NCORP phase 3 RCT

BACKGROUND: Despite guideline-consistent antiemetic prophylaxis, persistent chemotherapy-induced nausea remains common, and comparative phase 3 evidence for olanzapine versus prochlorperazine is limited. We evaluated whether adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduces persistent nausea compared with placebo. METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase 3 trial at 23 NCORP community oncology sites (April 2018-January 2024), women 18 years or older with breast cancer receiving moderately or highly emetogenic chemotherapy who recorded a Cycle 1 nausea score of 3 or greater (1-7 scale) were randomized 1:1:1 during Cycle 2 to placebo, prochlorperazine (10 mg every 8 hours, Days 1-4), or olanzapine (10 mg once daily, Days 1-4), added to netupitant/palonosetron plus dexamethasone. The primary outcome was change in average nausea from Cycle 1 to Cycle 2; the key secondary outcome was change in maximum nausea. RESULTS: Among 1363 screened patients, 310 comprised the intention-to-treat population (placebo, 91; prochlorperazine, 110; olanzapine, 109). Compared with placebo, average nausea improved with prochlorperazine (between-group difference, -0.44; P=.01) and olanzapine (-0.57; P=.001). Olanzapine reduced maximum nausea more than prochlorperazine (difference, -0.59; P=.02) and improved FACT-G quality-of-life scores over placebo (difference, 4.91; P=.006) and prochlorperazine (5.80; P=.001). Adverse events were primarily grade 1-2, with no toxicity-related discontinuations. CONCLUSIONS: Adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduced persistent chemotherapy-induced nausea compared with placebo. Olanzapine produced greater improvement in maximum nausea and quality of life than prochlorperazine and is an effective escalation option, with prochlorperazine a reasonable alternative when olanzapine is unsuitable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03367572.

Authors

Institutions

Publication Details

Journal
JNCI Journal of the National Cancer Institute
Published
2026-11-12
DOI
https://doi.org/10.1093/jnci/djag404
Primary Topic
Nausea and vomiting management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Olanzapine or prochlorperazine added to antiemetic therapy for persistent chemotherapy-induced nausea: an NCORP phase 3 RCT

Samer S. Kasbari, Jeremy McGuire, Luke Joseph Peppone, Belal Firwana et al.
JNCI Journal of the National Cancer Institute
Nausea and vomiting management
article

Olanzapine or prochlorperazine added to antiemetic therapy for persistent chemotherapy-induced nausea: an NCORP phase 3 RCT

Samer S. Kasbari, Jeremy McGuire, Luke Joseph Peppone, Belal Firwana, Charles Stewart Kamen, Thomas James Saphner, Joseph A. Roscoe, Gary R. Morrow, Joseph John Guido, Chunkit Fung, Michelle C. Janelsins, Eva Culakova, Kevin Spath, Riham Alieldin, Chin-Shang Li, Katherine Reith
article en

Abstract

BACKGROUND: Despite guideline-consistent antiemetic prophylaxis, persistent chemotherapy-induced nausea remains common, and comparative phase 3 evidence for olanzapine versus prochlorperazine is limited. We evaluated whether adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduces persistent nausea compared with placebo. METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase 3 trial at 23 NCORP community oncology sites (April 2018-January 2024), women 18 years or older with breast cancer receiving moderately or highly emetogenic chemotherapy who recorded a Cycle 1 nausea score of 3 or greater (1-7 scale) were randomized 1:1:1 during Cycle 2 to placebo, prochlorperazine (10 mg every 8 hours, Days 1-4), or olanzapine (10 mg once daily, Days 1-4), added to netupitant/palonosetron plus dexamethasone. The primary outcome was change in average nausea from Cycle 1 to Cycle 2; the key secondary outcome was change in maximum nausea. RESULTS: Among 1363 screened patients, 310 comprised the intention-to-treat population (placebo, 91; prochlorperazine, 110; olanzapine, 109). Compared with placebo, average nausea improved with prochlorperazine (between-group difference, -0.44; P=.01) and olanzapine (-0.57; P=.001). Olanzapine reduced maximum nausea more than prochlorperazine (difference, -0.59; P=.02) and improved FACT-G quality-of-life scores over placebo (difference, 4.91; P=.006) and prochlorperazine (5.80; P=.001). Adverse events were primarily grade 1-2, with no toxicity-related discontinuations. CONCLUSIONS: Adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduced persistent chemotherapy-induced nausea compared with placebo. Olanzapine produced greater improvement in maximum nausea and quality of life than prochlorperazine and is an effective escalation option, with prochlorperazine a reasonable alternative when olanzapine is unsuitable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03367572.

JNCI Journal of the National Cancer Institute
Missouri Baptist Medical Center (US), University of Rochester Medical Center (US), Aurora BayCare Medical Center (US), University of Rochester (US)
Nausea and vomiting management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon